ReElement Technologies stock soars after securing $1.4B government deal
Director Gary M. Pfeiffer of Quest Diagnostics Inc (NYSE:DGX), a $20.3 billion healthcare services provider with strong financial health according to InvestingPro, sold 1,482 shares of common stock on October 22, 2025, at a price of $182.4, for a total transaction value of $270,316. The stock, which has delivered a 22% return over the past year, is currently trading above its Fair Value.
Following the transaction, Pfeiffer directly owns 29,431 shares of Quest Diagnostics.
On October 23, 2025, Pfeiffer also engaged in an intra-plan transfer involving 4413.284 shares of Phantom Stock, moving them from the company stock fund to another investment option within the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors. These phantom common stock units, payable in cash, represented an equivalent number of Quest Diagnostics’ common stock shares.
In other recent news, Quest Diagnostics reported its third-quarter earnings for 2025, surpassing expectations with an adjusted earnings per share (EPS) of $2.60 compared to the forecasted $2.50. The company’s revenues also exceeded projections, reaching $2.82 billion against the expected $2.73 billion. Following these results, Quest Diagnostics raised its fiscal year 2025 guidance, indicating a positive outlook. Truist Securities responded to these developments by raising its price target for Quest Diagnostics from $195 to $205, maintaining a Hold rating on the stock. Similarly, Leerink Partners increased its price target from $203 to $210, citing a favorable environment in the laboratory services sector and stable reimbursement and utilization trends. Both analyst firms highlighted the strong third-quarter performance as a key factor in their revised assessments. These recent developments reflect a period of strong financial performance and positive sentiment from analysts regarding Quest Diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.